2
Lifestyle and dietary efforts have known benefits for the prevention of cardiovascular disease (CVD) (1, 2) . In addition, prescriptive approaches for cardiovascular risk reduction include treatment of elevated blood pressure, and anti platelet therapy with low dose aspirin, particularly within subjects at higher risk such as those with known CVD (3, 4) . Beyond these interventions, our current pharmacopoeia for the prevention and treatment of CVD are in large part based upon manipulation of lipid and lipoprotein targets. The dose-dependent relationship between circulating levels of low density lipoprotein cholesterol (LDL) and incident CVD risks in population studies (5) and the unequivocal benefit of therapies that lower LDL (6,7) have prompted its central role in the approach to risk prediction and preventive strategies. Yet, while high potency statin therapy has proven efficacy for both primary and secondary prevention subjects (6) (7) (8) , many patients with established CVD have "normal" LDL levels, though likely above ideal (9), often without clear alternative risk factors.
Although some experts feel the current LDL target goals are still too high, many subjects cannot even reach these goals, much less the lower treatment goals now being advocated with current agents. Thus, there is significant unmet need for additional agents to help subjects achieve appropriate therapeutic targets. Further, the polygenetic / causal nature of CVD suggests that there are additional factors that play contributory roles in the development and progression of CVD, which have yet to be appropriately leveraged as therapeutic targets. Indeed, subject with CVD are already typically placed on poly-pharmacy, yet substantial residual risk still exists, and few new agents have made it to use in the past decade in patient care for prevention of CVD and its complications. Cardiovascular therapeutics faces significant hurdles, and the demonstration of a new drug with proven efficacy for reduction in hard endpoints (incident heart attack, stroke and death) on top of high potency statin therapy has yet to be realized.
Despite these obstacles, the magnitude of the problem is staggering, and "the prize" for those who usher in the next generation of cardiovascular therapeutics can not be under estimated. While mortality rates from CVD have reduced, the prevalence of major risk factors like obesity and diabetes are rising.
Fully one in three individuals in industrialized societies will be affected by CVD, and approximately one in three subjects will die from CVD (10) . With CVD as the single largest cause of morbidity and mortality in industrial societies and the significant health care burden of obesity and diabetes, it is perhaps not too surprising that a multitude of novel therapeutic approaches are under investigation, with many already undergoing early clinical trials in humans.
In this issue, we launch the first installment of a series of review articles for a new JLR Thematic Review Series entitled "New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases". In the first review, Bart Staels and colleagues discuss "Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular diseases" (11) . Bile acid sequestrants were among the first lipid lowering agents with proven efficacy in LDL lowering and CVD event risk reduction in use (12) . (16) . Over half a century ago, Glomset identified LCAT as the key protein mediating cholesterol esterification and "plasma fatty acid trasferase" activity (17) . Over the ensuing 50 years, numerous studies have focused on LCAT as a pivotal enzyme in HDL maturation and remodeling; yet its role in reverse cholesterol transport and atherosclerotic CVD remains in debate. In this review, the structure, function, and role of LCAT in atherosclerosis in multiple animal models and humans are 6 extensively discussed. In addition, insights into the role of LCAT in CVD and other processes through genetic studies are discussed. Finally, efforts to increase LCAT levels by a variety of strategies as a novel CVD therapeutic are reviewed.
These are exciting times in the cardiometabolic pharmacology arena, with a large number of novel therapeutic targets under investigation. We hope that the readers of JLR enjoy the present and future series of review articles that will be forthcoming in the Thematic Review Series "New Lipid and Lipoprotein Targets for the Treatment of Cardiometabolic Diseases". 
